A Johnson & Johnson medical device prevailed in the U.S. Court of Appeals for the Sixth Circuit when the doctor that sued the company for trade secret violations failed to show proper similarity between his heart surgery device and J&J’s alleged copy.
The Securities and Exchange Commission has reached a $25 million settlement with a company it probed for allegedly defrauding thousands of terminally ill patients by manipulating their life insurance policies.
Merrill Lynch & Co. has been roped into the wide-ranging investigation of alleged conflicts of interest in the pension fund consulting industry, after receiving a subpoena from the Securities and Exchange Commission.
Tiny electric engine maker Solomon Technologies Inc., whose patent infringement suit against auto giant Toyota stalled due to troubles financing the litigation, will proceed after the company secured funds to continue pressing its case.
Dissatisfied with a sentence imposed by a California court on former CEO Henry Yuen, Gemstar TV-Guide has asked Florida prosecutors to investigate the $248 million accounting fraud allegedly orchestrated by Yuen during his tenure with the company.
The Securities and Exchange Commission has entered a final judgment against a Florida financial services company and its president, who the Commission alleges failed to supervise an agent who defrauded investors of $15.5 million.
Unnamed employees at insurance giant American International Group Inc. (AIG) have received notices of an impending investigation from the Securities and Exchange Commission, according to the company’s chief executive officer Martin Sullivan.
French pharmaceutical giant Sanofi-Aventis Group Inc. failed in federal court to stop a publisher from using the name of its yet-to-be-approved obesity drug in a news website’s address.
Eager to brandish its coast-to-coast credentials in intellectual property litigation, Philadelphia’s Duane Morris is quickly building a national platform by hiring laterals from competing firms across the U.S.
A federal judge has granted Abbott Laboratories Inc.’s request for a preliminary injunction against Ranbaxy Laboratories Ltd. and Andrx Corp. over its antibiotic Biaxin XL.
A plea bargain by a former expert witness could whip up a storm for Milberg Weiss, amid allegations of kickbacks to lead plaintiffs by the firm that paved the way for the modern securities class-action industry.
Drug maker Novartis AG’s acquisition of Chiron Corp. will expand the Swiss company’s footprints in the U.S. biotech market even as its generics division braces for a battle to launch the first generic biotech drugs in the United States.
Investors took legal action against drug maker Andrx Corp. Tuesday, accusing the pharmaceutical company of violating federal securities laws and misrepresenting the approval status of new drug applications with the U.S. Food and Drug Administration.
After filing a new suit earlier this week, Biovail Laboratories now has two patent infringement lawsuits pending against Andrx Pharmaceuticals in the same court over the same drug.
Generic drug maker Alphapharm Pty Ltd. must steer clear of blockbuster antidepressant Lexapro for now as part its settlement agreement with Forest Laboratories Inc., ending litigation launched in May 2004.
Managed healthcare company AmeriGroup Corporation is facing a class-action lawsuit from purchasers of its common stock for allegedly withholding damaging financial results during a five-month period to mislead investors.
In a case that could end up costing Johnson & Johnson millions more, a federal jury has ruled that the health-care products giant knowingly infringed a patent held by two Florida doctors and ordered the company to pay the breast cancer specialists $2 million.
Israeli drug maker Teva Pharmaceutical Industries Ltd. is seeking to produce a generic version of the schizophrenia drug Seroquel, which garnered drug originator AstraZeneca $2 billion in worldwide sales last year.
Belgian drugmaker UCB Societe Anonyme has sued IVAX Corporation in federal court, seeking protection of its popular epilepsy drug Keppra from generic competition before the expiration of its patent.
Toyota’s hybrid Prius has been drawing attention from consumers and patent holding companies alike, with yet another small transmission company asserting an obscure patent against the car maker.